

# National Eczema Association for Science & Education Annual Report

For the fiscal year ending June 30, 2003  
and the six-month fiscal year ending December 31, 2003



# National Eczema Association

for Science & Education



## MISSION

The National Eczema Association for Science and Education (NEASE) works to improve the health and the quality of life of all persons living with atopic dermatitis/eczema, providing emotional support, information, and resources to those who have the disease as well as their loved ones, while raising public awareness of the disease.

*The National Eczema Association for Science and Education meets the Good Operating Practices Standards of the National Health Council.*



*Dear Nease Supporters:*

The past eighteen months have been a transformational time for the National Eczema Association for Science and Education (NEASE). Our database list is nearly triple the size it was back in the summer of 2002, due in large part to our alliance with the National Alopecia Areata Foundation (NAAF) beginning in January 2003. We have also rededicated ourselves to earning the support of our constituents, both philosophically and financially.

The year 2003 began with a three-day intensive retreat attended by the NEASE Board of Directors and staff. The resulting “To Do” list helped us clarify and define NEASE policies, and it enabled us to meet the Good Operating Practices Standards required for membership in the National Health Council (NHC). Membership in this organization gives NEASE a recognized “Seal of Approval” that helps to assure contributors that we are a responsible and responsive organization. We have always strived for these characteristics, and we are pleased to be officially recognized for them. Perhaps more importantly, this formalization of policies and procedures is an aid to growth so that expanded activities and personnel changes can be accommodated more easily.

Early in 2003 we moved our office to San Rafael, California, where we share space, resources, and expertise with NAAF. This strategic and economic move has proven successful for both organizations.

Here are some highlights of NEASE’s many achievements in 2003:

- NEASE made plans for and announced the date of its first annual patient conference (July 16 to 18, 2004).
- NEASE determined to fund important atopic dermatitis/eczema research and issued a call for research grant applications in major medical journals.
- NEASE increased its involvement with the Coalition of Skin Diseases (CSD), formerly the Coalition of Patient Advocates for Skin Disease Research (CPASDR), helping to build a united front of patient advocates that work diligently to secure increased skin disease research through the National Institutes of Health (NIH).
- NEASE sponsored a major media campaign to alert the public about the dangers of smallpox immunization to people with atopic dermatitis/eczema.
- NEASE revised and improved several brochures and fact sheets covering items of specific interest to atopic dermatitis/eczema patients.

To make further progress, we need your ongoing support. As a 501(c)(3) organization, it is crucial we secure substantial funding from you, our constituents. The number of people suffering from eczema in the United States is immense, and we know we are reaching only a small fraction of those we could help. As we enter this new period of growth, your contributions will help us expand our reach to include more people whose eczema seriously affects their lives.

Sincerely,

A handwritten signature in cursive script that reads "Philip S. Crosby".

Philip S. Crosby  
*Chair, NEASE Board of Directors*


## GROWTH in Supporting Our Mission

The National Eczema Association for Science and Education (NEASE) is proud to list its accomplishments in supporting its mission for the fiscal year ending June 30, 2003, and the six-month fiscal year ending December 31, 2003.

*The all-volunteer NEASE Board of Directors met its commitment to improve all functions of the Association.*

- The Board held a three-day strategic planning retreat to establish short-term and long-term organizational goals.
- The Board developed policies that brought NEASE into compliance with the Good Operating Practices Standards of the National Health Council.
- The Board set forth specific strategies to accomplish NEASE's goals in three key areas: support, education, and research.
- The Board formed an alliance with NAAF, another nonprofit patient advocacy organization, enabling NEASE to share infrastructure costs and redirect those savings into programs.





**SUPPORT  
EDUCATION  
RESEARCH**



## Growth in Improving **SUPPORT** Functions

*The NEASE Board and staff worked as a team to improve support functions.*

- NEASE hired a full-time staff person to handle requests for support and information in a timely and efficient manner.
- NEASE redesigned its newsletter, *The Advocate*, to make it more informative and more patient friendly. It also set and met schedules for the newsletter to be distributed quarterly.
- NEASE tripled the size of its database in just six months.
- NEASE sent over 20,000 information packets and brochures in response to public and organizational requests.
- NEASE researched and compiled helpful information for everyday living with eczema.
- NEASE committed to planning its first annual patient conference to be held in the summer of 2004. This conference encompasses an event-packed three-day weekend where:
  - Children and adults with atopic dermatitis/eczema meet others to exchange ideas and support; where people become empowered and realize they are not alone;
  - The latest medical and research information is presented;
  - Children and adults visit Capitol Hill to educate legislators on this disease and to advocate for increased funding for medical research; and
  - Planned activities include Children's Conference Camp, Medical and Research Talks, Inspirational Talks, a Medical Question-and-Answer Session, over fifteen Breakout Support Sessions, and the opportunity to educate US Senators and Representatives.

**The more people we educate the more  
people will find us and the more people will  
understand the complexities of living with  
this disease.**





## Growth in Outreach and EDUCATION

*The NEASE Board and staff worked as a team to educate the public, medical professionals, and policymakers about atopic dermatitis/eczema.*

- NEASE staffed an informational booth and attended scientific sessions on atopic dermatitis/eczema at the American Academy of Dermatology, the Dermatology Nurses' Association, and the Society for Investigative Dermatology meetings.
- NEASE participated in advocacy activities as a member of the Coalition of Skin Diseases, promoting increased medical research funding at the National Institutes of Health (NIH).
- NEASE participated in NIAMS Day on Capitol Hill in Washington, DC, as part of a coalition of professional and voluntary agencies in support of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). NIAMS is one of the main institutes at the NIH that funds research in atopic dermatitis/eczema.
- NEASE testified before the United States House Subcommittee on Appropriations on Labor, Health, and Human Services, Education, and Related Agencies in May 2003. In oral testimony, NEASE Board member Kelly Woods-Farrell conveyed the everyday problems of dealing with atopic dermatitis/eczema and the need for more funding for biomedical research into the disease.
- NEASE had over 35 placements in print, Internet, and broadcast media during its public awareness campaign, (See page 8 for a partial listing.)





## NEASE sent out hundreds of news releases, and it had the following media placements (this is a partial listing):

### PERIODICALS

*Coping with Allergies & Asthma* (Franklin, TN)

Date: June 15, 2003

Details: This consumer magazine for allergy and asthma fighters printed background and contact information on NEASE.

*The New York Times* (New York, NY)

Date: April 29, 2003

Headline: "When Life in Your Own Skin is Agony"

*American Family Physician* (Leawood, KS)

Date: April 15, 2003

Headline: "Smallpox Vaccine in Persons with Eczema"

*The Gazette* (Cedar Rapids, IA)

Date: April 12, 2003

Headline: "Eczema: The Itch that Rashes"

*The Post-Star* (Glen Falls, NY)

Date: April 8, 2003

Details: An article detailed the possible vaccination reactions and who should not get the vaccine, including those with eczema.

*Rocky Mountain News* (Denver, CO)

Date: April 1, 2003

Details: An article detailed the risks associated with the vaccine and cautioned those with eczema to not get the vaccine.

*Dermatology Times* (Cleveland, OH)

Date: March 2003

Headlines: "Quick Hitters Top 10"

A condensed look at breaking news in the world of dermatology Bio-warfare.

*St. Paul Pioneer Press* (Saint Paul, MN)

Date: March 24, 2003

Headline: "Smallpox Vaccine Warning"

*The Tampa Tribune* (Tampa, FL)

Date: March 23, 2003

Headline: "Eczema Patients Warned about Smallpox Vaccine"

*Cape Cod Times* (Hyannis, MA)

Date: March 18, 2003

Headline: "Smallpox Vaccine Update"

*Fairbanks Daily News-Miner* (Fairbanks, AK)

Date: March 18, 2003

Headline: "Eczema Patients at Risk from Vaccine"

*Huron Daily Tribune* (Bad Axe, MI)

Date: March 13, 2003

Headline: "Smallpox Vaccine Could Harm Eczema Patients, Group Says"

*Rochester Democrat and Chronicle* (Rochester, NY)

Date: March 12, 2003

Headline: "Smallpox Warning"

*The Courier-Journal* (Louisville, KY)

Date: March 6, 2003

Headline: "Vaccine-Eczema Danger"

*Nurseweek: Mountain West Edition*

Date: March 3, 2003

Headline: "Smallpox Vaccine: Making an Informed Decision"

*San Jose Mercury News*

Date: February 27, 2003

<http://www.bayarea.com/mld/mercurynews/5274388.htm>

*USA Today*

Date: Feb. 25, 2003

[http://www.usatoday.com/news/health/2003-02-25-smallpox-usat\\_x.htm](http://www.usatoday.com/news/health/2003-02-25-smallpox-usat_x.htm)

*Newsday*

Date: Feb. 25, 2003

<http://www.newsday.com/news/health/ny-lipox253146301feb25.story>

*Nurseweek: California Edition*

Date: February 24, 2003

Headline: "Smallpox Vaccine: Making an Informed Decision"

*Guymon Daily Herald* (Guymon, OK)

Date: February 22, 2003

Headline: "Childhood Rashes May Be Caused by Atopic Dermatitis"

*American Freedom News*

Date: February 19, 2003

[http://www.americanfreedomnews.com/archives/news\\_archives/news\\_pages/02\\_feb\\_2003/news\\_arc\\_02x19x03.htm](http://www.americanfreedomnews.com/archives/news_archives/news_pages/02_feb_2003/news_arc_02x19x03.htm)

*St. Louis Front Page* (online news)

Date: February 18, 2003

<http://www.slfp.com/Community/HealthNews.htm>

*CBS Marketwatch*

Date: February 18, 2003

<http://cbs.marketwatch.com/news/newsfinder/newsArticles.asp?guid={8CA25C20-F434-4E6A-B76C-B9F13F3E96FE}&siteid=mkty&archive=thirdtrue>

*Yahoo Finance*

Date: February 18, 2003

[http://biz.yahoo.com/bw/030218/180409\\_1.html](http://biz.yahoo.com/bw/030218/180409_1.html)

### BROADCASTS

**Healthline Radio** (Washington, DC)

Date: April 30, 2003

Details: Healthline Radio conducted an interview with Dr. Amy Paller.

**KTLA Television**

Date: April 9, 2003

Details: Story included an interview with Dr. A. Paul Kelly

**NJN/The New Jersey Network**

Date: March 13, 2003

Details: Story included an interview with Dr. Frank Murphy.

**KRCG-TV**

(a CBS affiliate in Holts Summit, MO)

Date: February 18, 2003

Details: Segment on Eczema at 10 p.m.

**KFSM** (a station owned by The New York

Times Company reaching Arkansas and East Oklahoma)

Date: February 19, 2003

<http://www.kfsm.com/Global/story.asp?s=%20%201140276>





## Growth in Funding RESEARCH

*The NEASE Board and staff committed to funding medical research in areas that will benefit those with atopic dermatitis/eczema.*

- We set the following Priority Areas of Emphasis for current and future research:
  - Itch and itch management
  - Inflammation/neuro-inflammation
  - Dry Skin/Xerosis
  - Health care outcomes
  - Secondary infections

Other areas of innovative research are considered based on scientific merit.

- NEASE staff prepared promotional content for the grant application flyer distributed via mail and email throughout the world. Grant applications were also posted on the NEASE Web site.
- We restructured the NEASE Scientific Advisory Committee to better utilize the committee's collective expertise, and we established an outside Peer Review Committee to evaluate research grant applications online using pass code protected access.
- We actively promoted research and development of drugs to benefit those with atopic dermatitis/eczema to pharmaceutical companies.
- NEASE sought to effectively use its Web site, its newsletter, *The Advocate*, and targeted email distributions to inform atopic dermatitis/eczema patients of clinical research trials in their geographic areas.
- NEASE Board and Scientific Advisory Committee members and staff attended many scientific meetings and sessions on atopic dermatitis/eczema, including the conference "Immunomodulatory Drugs in the Treatment of Skin Diseases: What can we learn about Pathophysiology?" at the National Institutes of Health campus.
- NEASE committed funds to create a public information campaign warning patients with atopic dermatitis/eczema about the dangers posed by smallpox vaccines.
- NEASE created a public service announcement (PSA) for television use on the dangers of smallpox vaccination and sent copies to media outlets throughout the United States. Dr. A. Paul Kelly of the NEASE Scientific Advisory Committee is the spokesperson for NEASE on the PSA.

## Excerpt from Public Service Announcement:

*The National Eczema Association for Science and Education is urging anyone who has ever suffered from atopic dermatitis/eczema, as well as those they live with, not to receive the smallpox vaccine unless they have been exposed to smallpox. The vaccine contains a live virus that can be potentially life threatening to those who have atopic dermatitis/eczema.*

*If you suffer from atopic dermatitis, do not take the vaccine. If you come in contact with someone else's vaccine site, immediately and thoroughly wash with soap and warm water and alert your physician.*



A screenshot of the National Eczema Association website. The page is titled "Call for Research Grant Applications" and is dated "Wednesday, June 16, 2004". The text on the page reads: "The National Eczema Association for Science and Education (NEASE) is sponsoring a call for research proposals to support research in atopic dermatitis/eczema. The NEASE Scientific Advisory Committee and Board of Directors approved the following as the Research Areas of Emphasis for current NEASE research funding: Itch and Itch Management, Inflammation/Neuro-Inflammation, Dry Skin/Xerosis, Health care outcomes/impact of the disease, and Secondary Infections. Other areas of innovative research will be considered based on scientific merit. These areas are inter-related and reflect the strong desire of patients and clinician/scientists for research to control itch and dryness with safe and effective treatments for atopic dermatitis/eczema. The application must be completed and submitted online at www.nationaleczema.org. Additionally, applicants must send the following by regular mail: one hard copy of their completed application, signed copy of the Research Grant Agreement, Institutional Data Form with all appropriate signatures, and IRB approval documentation. Applications and supporting materials must be submitted online AND also received at the NEASE office no later than Tuesday, August 3, 2004 by 5:00 PM PDT to be considered for funding." The contact information for the National Eczema Association for Science and Education is provided at the bottom: 8400 Redwood Highway, Suite 16D, San Rafael, CA, 94903, 415.499.3474 / 800.818.7546, Fax: 415.472.2316.



# FINANCIAL REPORT

## Statement of Financial Position June 30, 2003

### R. J. RICCIARDI CERTIFIED PUBLIC ACCOUNTANT

1000 FOURTH STREET • SUITE 725 • SAN RAFAEL, CALIFORNIA 94901 • TEL (415) 457-1215 • FAX (415) 457-6735

#### INDEPENDENT AUDITOR'S REPORT

Board of Directors  
National Eczema Association  
For Science and Education  
San Rafael, California

I have audited the accompanying Statement of Financial Position of National Eczema Association for Science and Education as of June 30, 2003, and the related Statement of Activities, Statement of Functional Expenditures, and Statement of Cash Flows for the year then ended. These financial statements are the responsibility of National Eczema Association for Science and Education's management. My responsibility is to express an opinion on these financial statements based on my audit.

I conducted my audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. I believe that my audit provides a reasonable basis for my opinion.

In my opinion, the financial statements referred to above present fairly in all material respects, the financial position of National Eczema Association for Science and Education as of June 30, 2003, and the results of its operations and changes in net assets and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

  
Ralph J. Ricciardi  
Certified Public Accountant

San Rafael, California  
November 25, 2003

#### **ASSETS**

|                           |           |
|---------------------------|-----------|
| Current assets:           |           |
| Cash and cash equivalents | \$ 68,726 |
| Accounts receivable       | 40,000    |
| Prepaid expenses          | 1,578     |

|                             |                |
|-----------------------------|----------------|
| <b>Total current assets</b> | <b>110,304</b> |
|-----------------------------|----------------|

|  |        |
|--|--------|
| Fixed assets, net of<br>accumulated depreciation | 11,822 |
|--|--------|

|                     |                  |
|---------------------|------------------|
| <b>Total assets</b> | <b>\$122,126</b> |
|---------------------|------------------|

#### **LIABILITIES AND NET ASSETS**

|                          |          |
|--------------------------|----------|
| Current liabilities:     |          |
| Accounts payable         | \$12,093 |
| Accrued vacation payable | 1,751    |

|                                  |               |
|----------------------------------|---------------|
| <b>Total current liabilities</b> | <b>13,844</b> |
|----------------------------------|---------------|

|                            |           |
|----------------------------|-----------|
| <b>Net assets</b>          |           |
| Unrestricted, undesignated | \$108,282 |

|                         |                |
|-------------------------|----------------|
| <b>Total net assets</b> | <b>108,282</b> |
|-------------------------|----------------|

|   |                  |
|---|------------------|
| <b>Total liabilities and net assets</b> | <b>\$122,126</b> |
|---|------------------|

*The Statement of Financial Position of the National Eczema Association for Science and Education as of June 30, 2003, was audited by R. J. Ricciardi Certified Public Accountants. A copy of the complete report, including notes, is available for public review from the National Eczema Association for Science and Education, 4460 Redwood Highway, Suite 16D, San Rafael, CA 94903-1953.*

**Statement of Activities**  
**For the Year Ended June 30, 2003**

|   | <b>Unrestricted</b> | <b>Temporarily<br/>Restricted</b> | <b>Total</b>     |
|---|---------------------|-----------------------------------|------------------|
| <b>Revenues:</b>  |                     |                                   |                  |
| Donations — General   | \$37,084            | -                                 | \$37,084         |
| Donations — Corporate   | 116,940             | -                                 | 116,940          |
| Donations — Marketable securities   | 2,242               | -                                 | 2,242            |
| Constituent development grant   | -                   | \$100,000                         | 100,00           |
| Newsletter Income   | 6,000               | -                                 | 6,000            |
| Brochures   | 2,236               | -                                 | 2,236            |
| Interest and dividend income  | 377                 | -                                 | 377              |
| Net realized and unrealized<br>gains (losses) on<br>marketable securities | (72)                | -                                 | (72)             |
| Net assets released from<br>restrictions                                  | 100,000             | (100,000)                         |                  |
| <b>Total revenues</b>   | <b>264,807</b>      |                                   | <b>264,807</b>   |
| <b>Expenditures:</b>  |                     |                                   |                  |
| Program services:   |                     |                                   |                  |
| Research  | \$5,780             | -                                 | \$5,780          |
| Public health education   | 153,632             | -                                 | 153,632          |
| <b>Total program services</b>   | <b>159,412</b>      | <b>-</b>                          | <b>159,412</b>   |
| Support services:   |                     |                                   |                  |
| Fundraising   | 42,552              | -                                 | 42,552           |
| Management and general  | 44,832              | -                                 | 44,832           |
| <b>Total support services</b>   | <b>87,384</b>       | <b>-</b>                          | <b>87,384</b>    |
| <b>Total expenditures</b>   | <b>\$246,796</b>    | <b>-</b>                          | <b>\$246,796</b> |
| Change in net assets  | 18,011              | -                                 | 18,011           |
| Net assets, beginning of period   | 90,271              |                                   | 90,271           |
| <b>Net assets, end of period</b>  | <b>\$108,282</b>    |                                   | <b>\$108,282</b> |

## FINANCIAL REPORT

## Statement of Financial Position December 31, 2003

### R. J. RICCIARDI

CERTIFIED PUBLIC ACCOUNTANT

1000 FOURTH STREET • SUITE 400 • SAN RAFAEL, CALIFORNIA 94901 • TEL (415) 457-1215 • FAX (415) 457-6735

#### INDEPENDENT AUDITOR'S REPORT

Board of Directors  
National Eczema Association  
For Science and Education  
San Rafael, California

I have audited the accompanying Statement of Financial Position of National Eczema Association for Science and Education as of December 31, 2003, and the related Statement of Activities, Statement of Functional Expenditures, and Statement of Cash Flows for the six months then ended. These financial statements are the responsibility of National Eczema Association for Science and Education's management. My responsibility is to express an opinion on these financial statements based on my audit.

I conducted my audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that I plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. I believe that my audit provides a reasonable basis for my opinion.

In my opinion, the financial statements referred to above present fairly in all material respects, the financial position of National Eczema Association for Science and Education as of December 31, 2003, and the results of its operations and changes in net assets and its cash flows for the six months then ended in conformity with accounting principles generally accepted in the United States of America.



Ralph J. Ricciardi  
Certified Public Accountant

San Rafael, California  
February 27, 2004

#### **ASSETS**

|                                |          |
|--------------------------------|----------|
| Current assets:                |          |
| Cash                           | \$55,905 |
| Unconditional promises to give | 207,500  |
| Prepaid expenses               | 2,439    |

**Total current assets** 265,844

|  |        |
|--|--------|
| Fixed assets, net of<br>accumulated depreciation | 10,508 |
|--|--------|

**Total assets** \$276,352

#### **LIABILITIES AND NET ASSETS**

|                          |         |
|--------------------------|---------|
| Current liabilities:     |         |
| Accounts payable         | \$3,433 |
| Accrued vacation payable | 1,616   |

**Total current liabilities** 5,049

|                            |           |
|----------------------------|-----------|
| <b>Net assets</b>          |           |
| Unrestricted, undesignated | \$269,303 |
| Temporarily restricted     | 2,000     |

**Total net assets** 271,303

**Total liabilities and net assets** \$276,352

*The Statement of Financial Position of the National Eczema Association for Science and Education as of December 31, 2003, was audited by R. J. Ricciardi Certified Public Accountants. A copy of the complete report, including notes, is available for public review from the National Eczema Association for Science and Education, 4460 Redwood Highway, Suite 16D, San Rafael, CA 94903-1953.*

**Statement of Activities**  
**For the Six Months Ended December 31, 2003**

|   | <b>Unrestricted</b> | <b>Temporarily<br/>Restricted</b> | <b>Total</b>     |
|---|---------------------|-----------------------------------|------------------|
| <b>Revenues:</b>  |                     |                                   |                  |
| Donations — General   | \$30,536            | -                                 | \$30,536         |
| Donations — Corporate   | 207,500             | -                                 | 207,500          |
| Donations — Marketable securities                                   | 1,355               | -                                 | 1,355            |
| Constituent development grant                                       | -                   | \$ 50,000                         | 50,000           |
| Brochures   | 1,330               | -                                 | 1,330            |
| Interest and dividend income  | 174                 | -                                 | 174              |
| Net realized and unrealized gains (losses) on marketable securities | (51)                | -                                 | (51)             |
| Net assets released from restrictions                               | 50,000              | (50,000)                          |                  |
| <b>Total revenues</b>   | <b>290,844</b>      |                                   | <b>290,844</b>   |
| <b>Expenditures:</b>  |                     |                                   |                  |
| Program services:   |                     |                                   |                  |
| Research  | \$5,256             | -                                 | \$5,256          |
| Public health education   | 80,392              | -                                 | 80,392           |
| <b>Total program services</b>                                       | <b>85,648</b>       | <b>-</b>                          | <b>85,648</b>    |
| Support services:   |                     |                                   |                  |
| Fundraising   | 25,015              | -                                 | 25,015           |
| Management and general  | 17,160              | -                                 | 17,160           |
| <b>Total support services</b>                                       | <b>42,175</b>       | <b>-</b>                          | <b>42,175</b>    |
| <b>Total expenditures</b>   | <b>\$127,823</b>    | <b>-</b>                          | <b>\$127,823</b> |
| Change in net assets  | 163,021             | -                                 | 163,021          |
| Net assets, beginning of period                                     | 106,282             | \$2,000                           | 108,282          |
| <b>Net assets, end of period</b>                                    | <b>\$269,303</b>    | <b>\$2,000</b>                    | <b>\$271,303</b> |

## NEASE Donors from July 1, 2002 to December 31, 2003

### Diamond Benefactors \$50,000 and above

#### Businesses

Fujisawa Healthcare, Inc., Deerfield, IL •  
Novartis Pharmaceuticals Corporation,  
East Hanover, NJ

### Grand Benefactors \$5,000 to \$9,999

Philip & Irene Crosby

#### Businesses

GlaxoSmithKline, Moon Township, PA

### Benefactors \$1,000 to \$2,499

Dr. J. Mark De May • Dr. Jon Hanifin •  
Vicki Kalabokes • James & Petree Knighton  
• Louis & Connie Loeb • Sally Price • Tom  
& Carolyn Reese • Kelly Woods-Farrell •  
Donald S. Young, J.D.

#### Businesses

Procter & Gamble, Cincinnati, OH •  
United Parcel Service, Ontario, CA

### Sponsors \$500 to \$999

Ellen Carnahan • John R. Crossen, PhD  
• Robert A. Dreelein, DDS • Jim & Beth  
Hendricks • Fred C. Hock Jr. • Dr. Lydia  
Jones • Katherine & Sean Keenan • Kelly  
Parker • Ande & Bruce Rosenblum •  
Frazer Steele • Ching-Yi Olivia Tam •  
Ann G. Trammell • Dr. Dale A. Wood

#### Businesses

Tap Pharmaceutical Products, Lake Forest, IL

#### Foundations

Gayden Family Foundation

### Grand Patrons \$250 to 499

Dr. Allen Adinoff • Gary S. Bailey •  
Dr. Lisa Beck • Bruce & Gracia Brentlinger •  
Wayne Ching • Mei Chung • Jeremy J. Drake  
• Larry D. Emerson – *In honor of*

Jessica Marie Emerson • Dan & Jamie  
Huber • Oliver M. Langenberg • Dr. Candace  
Lapidus • Christine Lehman • Rebecca  
Litke, PhD • Anastasia Savas • Dr. Marek A.  
Stawiski • Marilyn Taksel

#### Businesses

Psoriasis Treatment Center, Grand Rapids,  
MI • Southwest Asthma & Allergy Clinic,  
San Antonio, TX

### Patrons \$100 to \$249

John & Cindy Aintablian • Mark Anders •  
Martine Aniel-Pastor • Susan Baszynski •  
Margaret Berchtold • Dr. Robert M. Biondi •  
Tash Blackburn • Victoria Brennan •  
Dr. Dana Broussard-Perry • Deborah &  
Arthur Buckley • Mark & Jane Burke •  
Mary Louise Byrd • James & Hannah Carder  
• Ivy Chazen • Dr. Sarah Chamlin •  
Dr. Denise Chevalier • Anita Chung • Martin  
& Marjorie Cohn • Carl & Sue Ann Conrad  
• Lisa Creason • Ray B. Cumming • Dr. Mark  
V. Dahl • Steve Davis • Rosanne & James  
DeBragga • Chris De Los Santos •  
Dr. W. L. Dennison Jr. • Anne Merie  
Donoghue • Robert A. Dreelein • Kenny, Noah  
& Denise Driggers • Donna Drummond •  
Barbara Dundon • Ann Duvoneck • Carol  
A. Egger • Pam Engelken • Dr. Maria Elena  
Falcon • Tawna B. Farmer • Jennifer Ferrer •  
Dr. Martin Fiser • Charlene J. Fox • Victoria  
Gokson • William Golant • Elizabeth Gray •  
Selene Greenbaum • Noah Harlow • Harriet  
Hayes • Jeff Heald • Dr. W. Dean Henrichs •  
Leonard & Ann Marie Hom • Carolyn Hoppe  
• Dr. Raila Horne • Stephanie Hubelbank •  
Dr. Robert Hylander • Elwin & Wendy Ilano  
• Dr. Robert L. Jackson • Art Jeffers •  
Lynne Johnson—*In honor of family and  
friends* • Dr. Hank Kearse • Marilois D.  
Keith—*In honor of Paul Allen Keith Jr.* •  
Stephanie Kelly • Portia Kieser • Carolyn  
M. King • Ellen King • Dr. Frederick A. J.  
Kingery • Carol Lee • Luther Lee •

Minja & Young Lee • Lori Lerude • Mary  
Lofgren • John R. Manning • Herman G.  
Marin • Dr. Richard M. Martinez • Bridget  
R. McTighe • Annette McQuinn • Dola  
M. Miller • Roberta Stockman Ming • Dr.  
Warwick L. Morison • Vivian Murphy • Paul  
Mycroft • Bruce Nemanic • Emil Neroda •  
Tim O'Halla • Marilyn J. Ottaviano • Charles  
& Helene Pearson • Dr. Francisco M. Perez  
• John Pielemeier • Fredrica Pitterman •  
Dr. Douglas A. Plager • Frances Porter •  
Carrie Austin Prunty • Carlton Putnam •  
Dr. Debora Quigley • Dr. Anne Quinn •  
Dr. Gary Rachelefsky • Paul Reynolds •  
Rosaline Rimann • Dr. Mark Rinsky • Andrea  
J. Rogers • Julie Rohwein • Christine Roob •  
Dr. & Mrs. Harry L. Roth • Jim & Pam Ryan  
• Maureen Ann Ryan • Hilton Schwartz •  
Leslie Schwartz • Dr. Jerry M Shier •  
Juanita Shih • Gayle Slate • Warren & Andrea  
Spencer • Joyce Stanley • Sally Stevens • Dr.  
Frances Storrs • Donna Sutton • Mr. & Mrs.  
Lawrence Sweeney • Frank Vignal • Carol T.  
Violette • Angela N. Wagner • Eleanor Walker  
• Dr. Lewis H. Walker • Elizabeth Watson  
• Nancy Wills • Carol Wilson • Mr. & Mrs.  
Mark Wilson • Michelle Winstead, PhD •  
Annette Wray • Richard Yamato

#### Businesses

Allergy Medical Clinic, Los Angeles, CA •  
Arkansas Allergy Clinic, Little Rock, AR •  
Asthma & Allergy Center, Silver Spring, MD  
• Blue Mountain Family Practice,  
Blairsville, AL • Tri County Dermatology  
Associates, Cincinnati, OH

*We regret the omission of any names. If you  
find an error, please call the NEASE office.*

## NEASE Board of Directors

### Chair

*Philip Crosby*  
Chief Engineer  
Portland, OR

### Secretary

*Jon M. Hanifin, MD*  
Professor of Dermatology  
Oregon Health & Science University  
Portland, OR

### Chief Financial Officer

*John "Jack" R. Crossen, PhD,*  
Clinical Psychologist  
Portland, OR

*Irene Crosby*

Volunteer Patient Advocate  
Portland, OR

*Shelley F. Diamond, M.A.*  
Graduate Student  
San Francisco, CA

*Kelly Woods-Farrell*  
Volunteer Patient Advocate  
Lake Mary, FL

*Rebecca Litke, PhD*  
Professor, UCLA  
Sylmar, CA

*Thomas D. Reese, JD*  
Professional Neutral (mediator/arbitrator)  
Palo Alto, CA

*Susan J. Tofte, RN*  
Registered Nurse  
Oregon Health & Science University  
Portland, OR

*Donald S. Young, JD*  
Retired Attorney  
Ocean Ridge, FL

## NEASE Scientific Advisory Committee (2002-2003)

### Chair

*Kevin D. Cooper, MD*  
Chair, Department of Dermatology  
University Hospitals of Cleveland  
Cleveland, OH

### Vice Chair

*Alice Gottlieb, MD*  
Director, Clinical Research Center  
UMDNJ - Robert Wood Johnson  
Medical School  
New Brunswick, NJ

*Lisa A. Beck, MD*  
Associate Professor of Medicine &  
Dermatology  
Johns Hopkins Bayview Medical Center  
Johns Hopkins Asthma and Allergy Center  
Baltimore, MD

*Richard A. Clark, MD*  
Chair, Dermatology  
Stony Brook University  
Health Sciences Center  
SUNY Stony Brook  
Stony Brook, NY

*Mark V. Dahl, MD*  
Chair, Department of Dermatology  
Mayo Clinic Scottsdale  
Scottsdale, AZ

*Jon M. Hanifin, MD*  
Oregon Health & Science University  
Department of Dermatology  
Portland, OR

*A. Paul Kelly, MD*  
Chief, Division of Dermatology  
Martin Luther King Hospital  
Los Angeles, CA

*Kristin M. Leiferman, MD*  
University of Utah Health Sciences Center  
Department of Dermatology  
Salt Lake City, UT

*Donald Y. M. Leung, MD*  
National Jewish Medical & Research Center  
Department of Allergy  
Denver, CO

*Amy S. Paller, MD*  
Children's Memorial Hospital  
Division of Dermatology  
Chicago, IL

*Harry L. Roth, MD*  
University of California, San Francisco  
San Francisco, CA

*Hugh A. Sampson, MD*  
Mount Sinai School of Medicine  
Department of Pediatrics  
New York, NY

*Mary K. Spraker, MD*  
The Emory Clinic – Dermatology  
Atlanta, GA

*E. Richard Stiehm, MD*  
UCLA Medical Center  
Department of Pediatrics  
Los Angeles, CA

*Frances J. Storrs, MD*  
Oregon Health & Science University  
Department of Dermatology  
Portland, OR

## NEASE Professional Staff

### Interim CEO

*Vicki Kalabokes*

### Administrative Associate

*Joanne Langeraar*

National **Eczema** Association  
for Science & Education

4460 Redwood Highway, Suite 16D  
San Rafael, California 94903-1953  
800-818-7546 or 415-499-3474  
[www.nationaleczema.org](http://www.nationaleczema.org)